Adam Esq - BioLineRx General Compliance
| BLRX Stock | USD 0.32 0.23 41.82% |
Executive
Adam Esq is General Compliance of BioLineRx
| Address | Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 |
| Phone | 972 8 642 9100 |
| Web | https://www.biolinerx.com |
BioLineRx Management Efficiency
The company has return on total asset (ROA) of (0.3523) % which means that it has lost $0.3523 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7194) %, meaning that it created substantial loss on money invested by shareholders. BioLineRx's management efficiency ratios could be used to measure how well BioLineRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.3 in 2024. Return On Capital Employed is likely to rise to -1.43 in 2024. Debt To Assets is likely to rise to 0.16 in 2024, whereas Total Assets are likely to drop slightly above 53.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| James Murphy | Mustang Bio | 67 | |
| Robert Felsch | Ardelyx | N/A | |
| Rajvir Madan | Arcutis Biotherapeutics | N/A | |
| MD JD | Cidara Therapeutics | N/A | |
| Rafael MD | Aptose Biosciences | 52 | |
| Eugene Scavola | Verrica Pharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Samuel Berry | Fortress Biotech | N/A | |
| Caroline Diaz | Verona Pharma PLC | N/A | |
| Todd Tucker | Arcutis Biotherapeutics | N/A | |
| SPHR CCP | Cidara Therapeutics | N/A | |
| Elizabeth Esq | Ardelyx | 60 | |
| Sarah Singleton | Immunitybio | N/A | |
| Wendy McDermott | Lexicon Pharmaceuticals | 53 | |
| Lisa DeFrancesco | Lexicon Pharmaceuticals | 45 | |
| Richard MS | Mustang Bio | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| FRCS FACS | Immunitybio | 71 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Kristen Alexander | Lexicon Pharmaceuticals | 56 | |
| Andrew Fisher | Verona Pharma PLC | 54 | |
Management Performance
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.35 |
BioLineRx Leadership Team
Elected by the shareholders, the BioLineRx's board of directors comprises two types of representatives: BioLineRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLineRx. The board's role is to monitor BioLineRx's management team and ensure that shareholders' interests are well served. BioLineRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLineRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Ella Sorani, Vice President-Development | ||
| Raziel Fried, Treasurer Director | ||
| Adam Esq, General Compliance | ||
| Jael MSc, QA RA | ||
| CPA MBA, Chief Officer | ||
| Holly MBA, President USA | ||
| Advocate Kotler, Gen Officer | ||
| Liron MBA, Director Devel | ||
| John Lacey, Head Relations | ||
| Abi MD, Chief Officer | ||
| LLB BSc, Head Advisor |
BioLineRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLineRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (1.77) % | ||||
| Operating Margin | (1.07) % | ||||
| Current Valuation | 25.53 M | ||||
| Shares Outstanding | 79.94 M | ||||
| Shares Owned By Insiders | 8.53 % | ||||
| Shares Owned By Institutions | 3.09 % | ||||
| Number Of Shares Shorted | 1.06 M | ||||
| Price To Earning | (3.88) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.